![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Adis International
ISSN: 1173-5503
Source: PharmacoEconomics and Outcomes News, Vol.1, Iss.370, 2002-01, pp. : 7-7
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Paclitaxel plus cisplatin increases survival, costs in ovarian cancer
Inpharma, Vol. 1, Iss. 1345, 2002-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Paclitaxel plus cisplatin and lonidamine showed `good activity' in advanced ovarian cancer
Inpharma, Vol. 1, Iss. 1285, 2001-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Paclitaxel vs cyclophosphamide, + cisplatin, for ovarian cancer
Inpharma, Vol. 1, Iss. 1581, 2007-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Cisplatin plus paclitaxel superior in cervical cancer?
Inpharma, Vol. 1, Iss. 1284, 2001-01 ,pp. :